PanGen Biotech Inc. (KOSDAQ:222110)
5,170.00
+150.00 (2.99%)
At close: Aug 11, 2026
PanGen Biotech Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 13,707 | 13,417 | 14,673 | 7,315 | 6,501 | 7,936 |
Revenue Growth | -6.37% | -8.56% | 100.58% | 12.53% | -18.08% | 28.18% |
Gross Profit Gross Profit Growth | 4,441 | 4,498 | 5,139 | 971.8 | 642.47 | 515.69 |
Operating Income Operating Income Growth | 1,288 | 1,506 | 1,020 | -4,225 | -4,591 | -3,288 |
Net Income Net Income Growth | 2,065 | 2,051 | 943.69 | -4,489 | -4,494 | -3,310 |
Earnings Per Share EPS Growth | 145.51 | 146.00 | 82.00 | -420.00 | -421.00 | -324.00 |
EPS Growth | 7.85% | 78.05% | - | - | - | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Contract Manufacturing Organization (CMO) Contract Manufacturing Organization (CMO) Growth | 5,647 | 1,593 | 1,049 | 2,060 | 898.67 |
EPO Medicine EPO Medicine Growth | 5,642 | 3,410 | 3,796 | 3,606 | 3,548 |
Royalty Royalty Growth | 1,150 | 270.59 | 689.58 | 752.46 | 449.52 |
Technology Transfer (CDO) Technology Transfer (CDO) Growth | 623.13 | 968.99 | 546.52 | 1,226 | 1,163 |
Other Other Growth | 1,612 | 1,072 | 420.01 | 290.43 | 131.44 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 12,707 | 13,804 | 11,432 | 194.64 | 840.28 | 24,100 |
Total Debt Total Debt Growth | 1,010 | 962.44 | 818.54 | 2,018 | 5.49 | 18,699 |
Net Cash (Debt) Net Cash Growth | 11,697 | 12,841 | 10,614 | -1,823 | 834.79 | 5,402 |
Net Cash Growth | 14.66% | 20.99% | - | - | -84.55% | 1760.05% |
Net Cash Per Share Net Cash Per Share Growth | 859.15 | 953.30 | 922.27 | -170.60 | 78.21 | 528.69 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -275.57 | 189.81 | 2,987 | -3,451 | -3,503 | -3,324 |
Capital Expenditures CapEx Growth | -397.37 | -562.81 | -360.06 | -422.13 | -728.05 | -1,425 |
Free Cash Flow Free Cash Flow Growth | -672.93 | -373 | 2,627 | -3,873 | -4,231 | -4,749 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 32.40% | 33.52% | 35.02% | 13.29% | 9.88% | 6.50% |
Operating Margin | 9.39% | 11.23% | 6.95% | -57.76% | -70.62% | -41.44% |
Pretax Margin | 15.09% | 15.41% | 6.84% | -60.72% | -68.23% | -40.95% |
Profit Margin | 15.07% | 15.28% | 6.43% | -61.36% | -69.13% | -41.72% |
FCF Margin | -4.91% | -2.78% | 17.90% | -52.94% | -65.08% | -59.85% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 35.53 | 36.85 | 77.91 | - | - | - |
Forward PE | - | 91.30 | 91.30 | 91.30 | 91.30 | 91.30 |
P/FCF Ratio | - | - | 27.99 | - | - | - |
PS Ratio | 5.10 | 5.63 | 5.01 | 10.04 | 10.68 | 12.57 |